vs

Side-by-side financial comparison of FiscalNote Holdings, Inc. (NOTE) and Entrada Therapeutics, Inc. (TRDA). Click either name above to swap in a different company.

FiscalNote Holdings, Inc. is the larger business by last-quarter revenue ($22.2M vs $20.6M, roughly 1.1× Entrada Therapeutics, Inc.). On growth, FiscalNote Holdings, Inc. posted the faster year-over-year revenue change (-24.7% vs -65.2%). FiscalNote Holdings, Inc. produced more free cash flow last quarter ($-1.9M vs $-39.7M). Over the past eight quarters, Entrada Therapeutics, Inc.'s revenue compounded faster (6.4% CAGR vs -16.8%).

FiscalNote Holdings, Inc., or commonly FiscalNote, is a publicly traded software, data, and media company headquartered in Washington, D.C. The company was founded by Timothy Hwang, Gerald Yao, and Jonathan Chen in 2013. FiscalNote provides software tools, platforms, data services, and news through the FiscalNote Government Relationship Management (GRM) service, its core product. The company also uses an artificial intelligence platform to analyze proposed U.S. legislation based on key phrase...

Entrada Therapeutics is a clinical-stage biotechnology firm developing transformative intracellular therapies for serious rare diseases and high-unmet-need disorders. Its pipeline covers neuromuscular, metabolic, and central nervous system segments, serving global patients via healthcare partnerships.

NOTE vs TRDA — Head-to-Head

Bigger by revenue
NOTE
NOTE
1.1× larger
NOTE
$22.2M
$20.6M
TRDA
Growing faster (revenue YoY)
NOTE
NOTE
+40.6% gap
NOTE
-24.7%
-65.2%
TRDA
More free cash flow
NOTE
NOTE
$37.7M more FCF
NOTE
$-1.9M
$-39.7M
TRDA
Faster 2-yr revenue CAGR
TRDA
TRDA
Annualised
TRDA
6.4%
-16.8%
NOTE

Income Statement — Q4 FY2025 vs Q1 FY2025

Metric
NOTE
NOTE
TRDA
TRDA
Revenue
$22.2M
$20.6M
Net Profit
$-17.3M
Gross Margin
Operating Margin
-83.7%
-106.0%
Net Margin
-84.4%
Revenue YoY
-24.7%
-65.2%
Net Profit YoY
-173.8%
EPS (diluted)
$-2.81
$-0.42

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
NOTE
NOTE
TRDA
TRDA
Q4 25
$22.2M
Q3 25
$22.4M
Q2 25
$23.3M
Q1 25
$27.5M
$20.6M
Q4 24
$29.5M
$37.4M
Q3 24
$29.4M
$19.6M
Q2 24
$29.2M
$94.7M
Q1 24
$32.1M
$59.1M
Net Profit
NOTE
NOTE
TRDA
TRDA
Q4 25
Q3 25
$-24.9M
Q2 25
$-13.3M
Q1 25
$-4.3M
$-17.3M
Q4 24
$1.1M
Q3 24
$-14.9M
$-14.0M
Q2 24
$-12.8M
$55.0M
Q1 24
$50.6M
$23.5M
Operating Margin
NOTE
NOTE
TRDA
TRDA
Q4 25
-83.7%
Q3 25
-43.4%
Q2 25
-31.9%
Q1 25
-50.0%
-106.0%
Q4 24
-19.4%
-15.7%
Q3 24
-23.1%
-110.7%
Q2 24
-27.2%
56.4%
Q1 24
-35.6%
35.7%
Net Margin
NOTE
NOTE
TRDA
TRDA
Q4 25
Q3 25
-110.8%
Q2 25
-57.0%
Q1 25
-15.4%
-84.4%
Q4 24
3.0%
Q3 24
-50.7%
-71.7%
Q2 24
-43.6%
58.1%
Q1 24
157.6%
39.7%
EPS (diluted)
NOTE
NOTE
TRDA
TRDA
Q4 25
$-2.81
Q3 25
$-1.73
Q2 25
$-0.08
Q1 25
$-0.03
$-0.42
Q4 24
$1.88
$-0.20
Q3 24
$-1.33
$-0.35
Q2 24
$-0.09
$1.55
Q1 24
$0.37
$0.68

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
NOTE
NOTE
TRDA
TRDA
Cash + ST InvestmentsLiquidity on hand
$26.3M
$67.8M
Total DebtLower is stronger
$128.4M
Stockholders' EquityBook value
$62.0M
$417.3M
Total Assets
$255.1M
$486.5M
Debt / EquityLower = less leverage
2.07×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
NOTE
NOTE
TRDA
TRDA
Q4 25
$26.3M
Q3 25
$31.2M
Q2 25
$38.5M
Q1 25
$46.3M
$67.8M
Q4 24
$34.6M
$101.2M
Q3 24
$32.7M
$78.0M
Q2 24
$37.7M
$185.3M
Q1 24
$43.6M
$68.4M
Total Debt
NOTE
NOTE
TRDA
TRDA
Q4 25
$128.4M
Q3 25
$131.5M
Q2 25
$116.7M
Q1 25
$118.0M
Q4 24
$147.1M
Q3 24
$152.2M
Q2 24
$145.9M
Q1 24
$153.0M
Stockholders' Equity
NOTE
NOTE
TRDA
TRDA
Q4 25
$62.0M
Q3 25
$75.5M
Q2 25
$95.1M
Q1 25
$98.7M
$417.3M
Q4 24
$97.8M
$428.7M
Q3 24
$98.5M
$422.4M
Q2 24
$106.9M
$429.9M
Q1 24
$106.1M
$269.4M
Total Assets
NOTE
NOTE
TRDA
TRDA
Q4 25
$255.1M
Q3 25
$273.9M
Q2 25
$288.3M
Q1 25
$299.7M
$486.5M
Q4 24
$326.2M
$526.3M
Q3 24
$337.9M
$554.6M
Q2 24
$346.3M
$582.0M
Q1 24
$357.8M
$510.8M
Debt / Equity
NOTE
NOTE
TRDA
TRDA
Q4 25
2.07×
Q3 25
1.74×
Q2 25
1.23×
Q1 25
1.20×
Q4 24
1.50×
Q3 24
1.54×
Q2 24
1.36×
Q1 24
1.44×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
NOTE
NOTE
TRDA
TRDA
Operating Cash FlowLast quarter
$-279.0K
$-38.5M
Free Cash FlowOCF − Capex
$-1.9M
$-39.7M
FCF MarginFCF / Revenue
-8.7%
-192.9%
Capex IntensityCapex / Revenue
7.4%
5.6%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-18.6M
$-58.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
NOTE
NOTE
TRDA
TRDA
Q4 25
$-279.0K
Q3 25
$-8.3M
Q2 25
$-6.2M
Q1 25
$3.3M
$-38.5M
Q4 24
$-1.3M
$-31.6M
Q3 24
$-3.0M
$-24.3M
Q2 24
$-3.7M
$39.8M
Q1 24
$2.7M
$-25.5M
Free Cash Flow
NOTE
NOTE
TRDA
TRDA
Q4 25
$-1.9M
Q3 25
$-10.4M
Q2 25
$-7.7M
Q1 25
$1.3M
$-39.7M
Q4 24
$-3.4M
$-32.2M
Q3 24
$-5.4M
$-24.9M
Q2 24
$-6.5M
$38.8M
Q1 24
$1.0M
$-26.4M
FCF Margin
NOTE
NOTE
TRDA
TRDA
Q4 25
-8.7%
Q3 25
-46.2%
Q2 25
-33.0%
Q1 25
4.7%
-192.9%
Q4 24
-11.4%
-86.2%
Q3 24
-18.4%
-127.3%
Q2 24
-22.1%
41.0%
Q1 24
3.3%
-44.6%
Capex Intensity
NOTE
NOTE
TRDA
TRDA
Q4 25
7.4%
Q3 25
9.3%
Q2 25
6.4%
Q1 25
7.2%
5.6%
Q4 24
6.8%
1.7%
Q3 24
8.3%
3.3%
Q2 24
9.4%
1.1%
Q1 24
5.3%
1.4%
Cash Conversion
NOTE
NOTE
TRDA
TRDA
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
-27.94×
Q3 24
Q2 24
0.72×
Q1 24
0.05×
-1.09×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

NOTE
NOTE

Subscription$21.2M95%
Advisory Advertising And Other$1.0M5%

TRDA
TRDA

Segment breakdown not available.

Related Comparisons